JP2025510189A5 - - Google Patents
Info
- Publication number
- JP2025510189A5 JP2025510189A5 JP2024556559A JP2024556559A JP2025510189A5 JP 2025510189 A5 JP2025510189 A5 JP 2025510189A5 JP 2024556559 A JP2024556559 A JP 2024556559A JP 2024556559 A JP2024556559 A JP 2024556559A JP 2025510189 A5 JP2025510189 A5 JP 2025510189A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323257P | 2022-03-24 | 2022-03-24 | |
| US63/323,257 | 2022-03-24 | ||
| US202263405237P | 2022-09-09 | 2022-09-09 | |
| US63/405,237 | 2022-09-09 | ||
| US202263407979P | 2022-09-19 | 2022-09-19 | |
| US63/407,979 | 2022-09-19 | ||
| PCT/US2023/064941 WO2023183927A2 (en) | 2022-03-24 | 2023-03-24 | Humanized anti-cd45 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510189A JP2025510189A (ja) | 2025-04-14 |
| JP2025510189A5 true JP2025510189A5 (https=) | 2026-04-01 |
Family
ID=88102093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556559A Pending JP2025510189A (ja) | 2022-03-24 | 2023-03-24 | ヒト化抗ｃｄ４５抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11981741B2 (https=) |
| EP (1) | EP4490197A4 (https=) |
| JP (1) | JP2025510189A (https=) |
| CN (1) | CN119256014A (https=) |
| CA (1) | CA3246544A1 (https=) |
| WO (1) | WO2023183927A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118620078B (zh) * | 2024-07-09 | 2024-11-19 | 武汉爱博泰克生物科技有限公司 | 抗人cd45ra蛋白的抗体、抗体偶联物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029636B2 (en) * | 2008-02-05 | 2015-05-12 | Monsanto Technology Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| CN104710504B (zh) | 2009-07-22 | 2019-09-13 | 锕医药股份有限公司 | 用于制备放射性免疫缀合物的方法 |
| JP6047142B2 (ja) * | 2011-04-01 | 2016-12-21 | ウニヴェルズィテート シュトゥットガルト | 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用 |
| CA2861003C (en) * | 2012-01-13 | 2023-03-28 | Julius-Maximilians-Universitat Wurzburg | Dual antigen-induced bipartite functional complementation |
| EP3297684B1 (en) | 2015-05-21 | 2020-12-23 | Actinium Pharmaceuticals, Inc. | Infusion administration of conjugated monoclonal antibodies |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| WO2017155937A1 (en) | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| JP2020530280A (ja) * | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| WO2019084273A1 (en) * | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES |
| WO2020092655A1 (en) * | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
| WO2020132672A1 (en) * | 2018-12-21 | 2020-06-25 | Actinium Pharmaceuticals, Inc. | Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer |
| WO2020159656A1 (en) | 2019-02-01 | 2020-08-06 | Actinium Pharmaceuticals, Inc. | Molecules and their derivatives directed against cd45 |
| JP7650819B2 (ja) | 2019-04-24 | 2025-03-25 | ブイオーアール バイオファーマ インコーポレーテッド | 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用 |
| CA3137908A1 (en) * | 2019-04-25 | 2020-10-29 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
| US12605472B2 (en) | 2019-09-17 | 2026-04-21 | Actinium Pharmaceuticals, Inc. | Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof |
| WO2022040577A1 (en) | 2020-08-20 | 2022-02-24 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
-
2023
- 2023-03-24 JP JP2024556559A patent/JP2025510189A/ja active Pending
- 2023-03-24 WO PCT/US2023/064941 patent/WO2023183927A2/en not_active Ceased
- 2023-03-24 CN CN202380042580.8A patent/CN119256014A/zh active Pending
- 2023-03-24 CA CA3246544A patent/CA3246544A1/en active Pending
- 2023-03-24 EP EP23775928.7A patent/EP4490197A4/en active Pending
- 2023-09-11 US US18/464,847 patent/US11981741B2/en active Active
-
2024
- 2024-04-11 US US18/632,379 patent/US20240301081A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510189A5 (https=) | ||
| JP7475283B2 (ja) | キレート化された放射性核種に対する抗体 | |
| US11981741B2 (en) | Humanized anti-CD45 antibodies | |
| JP2018508188A5 (https=) | ||
| JP2021520832A5 (https=) | ||
| JP7582867B2 (ja) | キレート化された放射性核種に対する抗体および除去剤 | |
| US20240124590A1 (en) | Pd1 binding agents | |
| JP2022122865A5 (https=) | ||
| JP2024520188A5 (https=) | ||
| JP2019507580A5 (https=) | ||
| US20220267467A1 (en) | Polypeptide complex for conjugation and use thereof | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2022540610A5 (https=) | ||
| CN118475367A (zh) | 用于治疗和预防covid-19的组合物 | |
| JP2023533533A5 (https=) | ||
| JP2025003404A (ja) | 血液脳関門を通過するグラニュリンの送達のための化合物 | |
| WO2024055040A2 (en) | Humanized anti-cd45 antibodies | |
| US20230312742A1 (en) | CD38 antibodies for the treatment of human diseases | |
| JP2025130076A5 (https=) | ||
| US20150071853A1 (en) | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof | |
| JP2024504931A5 (https=) | ||
| WO2023277113A1 (ja) | Ｈｅｇ１タンパク質に結合するヒト化抗体 | |
| JP2023546277A5 (https=) | ||
| EP4428158A1 (en) | Lung cancer targeting human antibodies and therapeutic uses thereof | |
| ES2541907T3 (es) | Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos. |